IgM型多发性骨髓瘤:134例患者的多中心回顾性研究
该多中心回顾性研究纳入20个中心的134例IgM型多发性骨髓瘤患者,中位年龄65.5岁,男性占68%,中位总生存期为61个月;较高的ISS分期与更差的生存相关(P=0.02),其临床特征和结局与更常见的骨髓瘤亚型相似。
要点
- IgM型多发性骨髓瘤诊断需骨髓单克隆浆细胞>10%且存在任何大小的IgM单克隆副蛋白血症。
- 134例患者中贫血37%、肾功能不全43%、高钙血症19%、溶骨性病变70%。
- 中位总生存期61个月,较高ISS评分与更差生存相关(P=0.02)。
核心结论
- IgM型多发性骨髓瘤患者的临床特征和结局与更常见的骨髓瘤亚型相似。
研究设计与样本
- 多中心回顾性研究,纳入20个中心的134例IgM型多发性骨髓瘤患者。
主要发现
- 中位诊断年龄65.5岁,男性占68%。
- 贫血、肾功能不全、血钙升高和骨骼溶骨性病变分别见于37%、43%、19%和70%的患者。
- 中位血清IgM水平为2,895 mg dL-1,19%的患者水平>6,000 mg dL-1。
- ISS分期1、2、3期分别见于40例(33%)、54例(44%)、29例(24%)患者。
- 恶性细胞表达CD20者占58%、表达cyclin D1者占67%,t(11;14)是最常见的细胞遗传学发现(39%)。
关键数值与推荐
- 中位总生存期为61个月。
- 较高的ISS评分与更差的生存相关(P = 0.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mg dL-1 with 19% of patients presenting with levels >6,000 mg dL-1 . International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P = 0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.
引用
- Castillo JJ, Jurczyszyn A, Brozova L, et al. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017. PMID: 28383205. doi:10.1002/ajh.24753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。